A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

PHASE2RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

August 28, 2025

Study Completion Date

August 28, 2025

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

HRG2005 inhalation

Drug 1: dose 1; dose 2; dose 3

DRUG

Placebo to match HRG2005 inhalation

Drug 2

DRUG

Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Drug 3

DRUG

Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Drug 4

Trial Locations (1)

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY